Interleukin 27 (IL-27) is an immune-regulatory protein that is produced by tumor cells and many immune cells; however, its diverse effects are not well understood. Therefore, Dr. Anthony Phan is examining it to determine whether it’s responsible for pro-tumor or anti-tumor effects. Determining how IL-27 impacts T cell function within the tumor will be essential to understanding the complex tumor environment, and the insights produced from Dr. Phan's studies should provide important information that can aid the development of novel strategies that enable immunotherapy to further improve patient outcomes.
University of Pennsylvania | All Cancers | 2017 | Christopher A. Hunter, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Cell therapy development lagged in 2020, but is gaining ground again, a new CRI report shows.
CRI scientists will highlight cancer immunotherapy advances in the clinic at the 2021 ASCO annual meeting.